Federal Court concludes Minister of Health's decision not to reassess data protection for SPRAVATO in view of CUSMA is reasonable | Smart & Biggar

Before approving Janssen’s esketamine hydrochloride product (SPRAVATO) on May 20, 2020, the Minister of Health determined that it was not an “innovative drug” as defined by section...

Related Keywords

United States ,Canada ,Justice Manson ,Janssen Incv Canada Attorney ,Drug Regulations ,Canada United States Mexico Agreement ,Janssen Inc ,Attorney General ,